On the evening of March 12, 2017, the award ceremony of " the second (2016) China Pharmaceutical Innovative Brand Series Selection Activity" jointly sponsored by the Chinese Academy of Medical Sciences, the Chinese Academy of Traditional Chinese Medicine, the Chinese Medicine Promotion Association and the People's Network was held at the People's Daily. The purpose of this activity is to thoroughly publicize and implement the guiding spirit of general secretary Xi Jinping's " promoting the transformation of China manufacturing to China creation, the transformation of China's speed to China's quality, and the transformation of Chinese products to Chinese brands", promote the innovation and brand building of the pharmaceutical industry, and the optimization, upgrading and innovative development of the pharmaceutical industry. The chemical new drug Chidamide ( Epidaza?) of CHIPSCREEN BIOSCIENCES won the award of the most clinically valuable innovative drug in the second (2016) China Pharmaceutical Innovative Brand.

Chidamide is the first international subtype selective histone deacetylase (HDAC) oral inhibitor, a brand new molecular body with global patent protection, the national " 863" and " major new drug discovery" special achievement, and also the first original new drug authorized by China to be used in patents of developed countries such as the United States. It was approved and listed by China Food and Drug Administration (CFDA) in December 2014, and approved to be suitable for treating relapsed and refractory peripheral T-cell lymphoma patients. Compared with international PTCL, Chidamide has obvious advantages in subtype treatment, long-term benefits for patients' survival, and cost advantages which has been widely used in clinical treatment. More than 1,900 patients have benefited from Chidamide's treatment during the two-year marketing period. After Chidamide was listed on the market, CHIPSCREEN BIOSCIENCES also assumed corporate social responsibility. In order to prevent patients from becoming poor due to illness and help economically poor patients (subsistence allowances), peripheral T-cell lymphoma patients are carried out follow-up free medication programs and charity donation programs. In the past two years, it has assisted nearly 600 patients (as of February 2017), with the value of aid drugs exceeding 70 million yuan. At present, the clinical trials of Chidamide's monotherapy and its combination with other drugs are underway. The clinical trials in the United States, Japan, Taiwan and other places are also underway at the same time. Chidamide not only meets the urgent clinical needs of Chinese T-cell lymphoma patients, but also breaks the pattern of waiting for innovative drugs from foreign drug companies to enter China. It also means that Chinese lymphoma patients can use innovative drugs with the latest mechanism of action in the world under the condition that they only pay 1/10 of the imported drug price, bringing them survival benefits with better efficacy and safety.

Dr. Lu, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the award ceremony and delivered a speech on behalf of the award-winning guests. Chen Zhu, who is the vice-chairman of the Standing Committee of the 12nd National People's Congress and the chairman of the Central Committee of the Agricultural Labor Party, Sang Guowei, who is the vice-chairman of the Standing Committee of the 11st National People's Congress, Wang Guoqiang, who is the deputy director of the National Health and Family Planning Commission and the director of State Administration of Traditional Chinese Medicine, Wu Zhen, who is the deputy director of China Food and Drug Administration, He Wei, who is the deputy Secretary-General of the National Committee of the Chinese People's Political Consultative Conference and the vice-chairman of the Central Committee of the Agricultural Labor Party, Liu Qian, who is the former vice-chairman of the National Health and Family Planning Commission, Academicians of both houses in the medical fields such as Zhang Boli, Chen Kaixian, Ge Junbo, Wang guangji and Chen Jianfeng, as well-known experts, scholars, entrepreneurs active in the pharmaceutical industry, and representatives of the selected varieties, figures and enterprises.

The second Brand Selection Campaign is the same as the first. The Organizing Committee and Expert Evaluation Committee System are implemented. The chairman of the Organizing Committee is Academician Cao Xuetao, the president of the Chinese Academy of Medical Sciences, and Academician Zhang Boli, the president of the Chinese Academy of Traditional Chinese Medicine. At the same time, 46 authoritative expert groups from the drug research and clinical field were invited to become Expert Evaluation Committees. Under the leadership of three academicians, Chen Kaixian, Wang guangji and Chen Jianfeng, the Evaluation Committee carefully evaluated the shortlisted items in strict accordance with the evaluation criteria of " clinical, economic and social value". Based on the results of public recommendation and evaluation on the People's Net, the Committee selected three innovative medicines with the most clinical value, four pharmaceutical enterprises with the most innovative ability, four innovative figures with the most influence, three generic medicines with the most clinical substitution value and a lifetime achievement award for Chinese pharmaceutical innovation in recognition of promoting Chinese pharmaceutical innovation and improving Chinese pharmaceutical innovation policy.